SOPHiA GENETICS chair sells 44,381 shares

SOPHiA GENETICS SA Executive Chairman and director Jurgi Camblong reported option exercises and share sales executed pursuant to a duly adopted Rule 10b5-1(c) trading plan.

Rhea-AI Filing Summary

SOPHiA GENETICS SA Executive Chairman and director Jurgi Camblong reported option exercises and share sales executed pursuant to a duly adopted Rule 10b5-1(c) trading plan. On July 20, 2026, he exercised options for 4,581 ordinary shares at $3.16 per share and sold 4,581 shares at a weighted average $6.1654, in multiple trades between $6.10 and $6.20, plus 19,800 shares at a weighted average $6.3233, in trades between $6.30 and $6.37. On July 21, 2026, he sold 20,000 ordinary shares at a weighted average $6.6327, in trades between $6.60 and $6.72. A footnote states he continues to hold 4,641,476 derivative share options across remaining grant tranches.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 5 txns

Insider Camblong Jurgi

Role Executive Chairman

Sold 44,381 shs ($286K)

Approx. gross sale proceeds $286K

Approx. exercise cost $14K

Type	Security	Shares	Price	Value
Sale	Ordinary Shares F1, F4	20,000	$6.6327	$133K
Exercise	Share Option (Right to Buy) F5, F6	4,581	$0.00	$0.00
Sale	Ordinary Shares F1, F2	19,800	$6.3233	$125K
Exercise	Ordinary Shares F1	4,581	$3.16	$14K
Sale	Ordinary Shares F1, F3	4,581	$6.1654	$28K

Holdings After Transaction: Share Option (Right to Buy) — 0 contracts (Direct); Ordinary Shares — 3,492,822 shares (Direct)

Footnotes (6)

1. F1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.30 to $6.37, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.10 to $6.20, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.60 to $6.72, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. F5. The share options are fully vested and exercisable.
6. F6. Following the transaction reported on this line, the Reporting Person holds an aggregate total of 4,641,476 derivative share options across all remaining grant tranches with varying exercise prices.

Key Figures

Total shares sold: 44,381 shares Option shares exercised: 4,581 shares Option exercise price: $3.16 per share +4 more

7 metrics

Total shares sold 44,381 shares Aggregate ordinary-share sales reported across all sale transactions in this Form 4

Option shares exercised 4,581 shares Ordinary shares acquired via option exercise on July 20, 2026

Option exercise price $3.16 per share Conversion or exercise price of the share option exercised on July 20, 2026

Sale price for 19,800 shares $6.3233 per share Weighted average price for 19,800 ordinary shares sold on July 20, 2026

Sale price for 4,581 shares $6.1654 per share Weighted average price for 4,581 ordinary shares sold on July 20, 2026

Sale price for 20,000 shares $6.6327 per share Weighted average price for 20,000 ordinary shares sold on July 21, 2026

Remaining derivative options 4,641,476 options Aggregate derivative share options held after the reported transactions

Key Terms

Rule 10b5-1(c), weighted average price, derivative share options

3 terms

Rule 10b5-1(c) regulatory

"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

derivative share options financial

"holds an aggregate total of 4,641,476 derivative share options across all remaining grant tranches"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did SOPHiA GENETICS (SOPH) report for July 20, 2026?

On July 20, 2026, Executive Chairman Jurgi Camblong exercised options for 4,581 shares at $3.16 and sold 4,581 shares at $6.1654 plus 19,800 shares at $6.3233, all in multiple trades within disclosed price ranges under a Rule 10b5-1(c) plan.

What additional SOPHiA GENETICS (SOPH) insider sale occurred on July 21, 2026?

On July 21, 2026, Jurgi Camblong sold 20,000 ordinary shares of SOPHiA GENETICS at a weighted average price of $6.6327, executed in multiple trades at prices ranging from $6.60 to $6.72, as disclosed in the Form 4 footnote.

Were the SOPHiA GENETICS (SOPH) insider trades made under a Rule 10b5-1 plan?

Yes. A checkbox and footnote state the transactions were made pursuant to a duly adopted Rule 10b5-1(c) trading plan, indicating the trades followed a pre-established instruction rather than being discretionary at the time of execution.

How many derivative options does Jurgi Camblong still hold in SOPHiA GENETICS (SOPH)?

After the reported option exercise, a footnote states that Jurgi Camblong holds an aggregate total of 4,641,476 derivative share options across all remaining grant tranches, each with varying exercise prices, indicating substantial remaining option-based exposure.

What price ranges applied to the SOPHiA GENETICS (SOPH) insider share sales?

Weighted average prices reflect multiple trades. The 19,800-share sale occurred between $6.30 and $6.37, the 4,581-share sale between $6.10 and $6.20, and the 20,000-share sale between $6.60 and $6.72, according to detailed footnotes.

What options did the SOPHiA GENETICS (SOPH) Executive Chairman exercise in this Form 4?

He exercised a fully vested share option covering 4,581 ordinary shares at an exercise price of $3.16 per share, eliminating that specific option tranche (0 options remaining in that grant) and converting it into ordinary shares that were then sold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/22/2026 - 04:02 PM Accepted by SEC EDGAR 07/22/2026 - 04:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Camblong Jurgi

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Chairman

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	07/20/2026		S		19,800(1)	D	$6.3233(2)	3,512,822	D
Ordinary Shares	07/20/2026		M		4,581(1)	A	$3.16	3,517,403	D
Ordinary Shares	07/20/2026		S		4,581(1)	D	$6.1654(3)	3,512,822	D
Ordinary Shares	07/21/2026		S		20,000(1)	D	$6.6327(4)	3,492,822	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$3.16	07/20/2026		M			4,581	(5)	11/29/2028	Ordinary Shares	4,581	$0	0(6)	D

Explanation of Responses:

1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.30 to $6.37, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.10 to $6.20, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.60 to $6.72, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The share options are fully vested and exercisable.

6. Following the transaction reported on this line, the Reporting Person holds an aggregate total of 4,641,476 derivative share options across all remaining grant tranches with varying exercise prices.

Remarks:

	/s/ Elimara Brunetto as Attorney-in- Fact for Jurgi Camblong	07/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)